Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-042025
Filing Date
2025-05-12
Accepted
2025-05-12 16:06:07
Documents
60
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0238635-10q_relmada.htm   iXBRL 10-Q 450636
2 EXCLUSIVE LICENSE AGREEMENT BETWEEN TRIGONE PHARMA, LTD., AND RELMADA THERAPEUTI ea023863501ex10-2_relmada.htm EX-10.2 270646
3 CERTIFICATION ea023863501ex31-1_relmada.htm EX-31.1 11211
4 CERTIFICATION ea023863501ex31-2_relmada.htm EX-31.2 10979
5 CERTIFICATION ea023863501ex32-1_relmada.htm EX-32.1 4853
6 CERTIFICATION ea023863501ex32-2_relmada.htm EX-32.2 4340
  Complete submission text file 0001213900-25-042025.txt   4126950

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE rlmd-20250331.xsd EX-101.SCH 35069
8 XBRL CALCULATION FILE rlmd-20250331_cal.xml EX-101.CAL 23783
9 XBRL DEFINITION FILE rlmd-20250331_def.xml EX-101.DEF 190922
10 XBRL LABEL FILE rlmd-20250331_lab.xml EX-101.LAB 340684
11 XBRL PRESENTATION FILE rlmd-20250331_pre.xml EX-101.PRE 204219
62 EXTRACTED XBRL INSTANCE DOCUMENT ea0238635-10q_relmada_htm.xml XML 294119
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 25934760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)